Cirtran (CIRX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 4, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 18, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CIRX SEC filings page.
Cirtran (CIRX) reported $4.8M in revenue over the twelve months to Jun 30, 2026, up 336.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue rebounded, but margin compression and financing-dependent cash flow still define the operating model.
The latest rebound lifted revenue to$3.13M from$1.30M , but operating margin improved only to-4.1% from-42.5% , leaving profitability negative. At the same time, gross margin dropped from64.7% to49.3% ; higher volume therefore came with weaker economics per sales dollar, pointing to mix or direct-cost pressure rather than clean fixed-cost absorption.
In FY2025, financing cash flow of
Liabilities were
Financial Health Signals
Cirtran does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Cirtran scores -44.35, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($188K) relative to total liabilities ($27.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cirtran passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Cirtran reported a net loss of $702K while operations used $1.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Cirtran reported an operating loss of $130K against $823K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Cirtran generated $1.2M in revenue in Q2 2026. This represents an increase of 595.6% from the same quarter a year earlier. Against the prior quarter it is up 0.9%.
Cirtran's EBITDA was $161K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 183.7% from the same quarter a year earlier. Against the prior quarter it is up 340.7%.
Cirtran reported -$108K in net income in Q2 2026. This represents an increase of 80.8% from the same quarter a year earlier. Against the prior quarter it is down 104.9%.
Cirtran earned -$0.02 per diluted share (EPS) in Q2 2026. This represents an increase of 83.3% from the same quarter a year earlier. Against the prior quarter it is down 104.4%.
Cash & Balance Sheet
Cirtran held $158K in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Cirtran's gross margin was 52.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.9 percentage points.
Cirtran's operating margin was 13.7% in Q2 2026, reflecting core business profitability. Against the prior quarter it is up 10.6 percentage points. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Cirtran's net profit margin was -9.2% in Q2 2026, showing the share of revenue converted to profit. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
CIRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M+595.6% | $1.2M+152.0% | $2.0M+827.9% | $448K+75.1% | $168K-56.9% | $461K+7.3% | $221K+24.3% | $256K-66.6% |
| Cost of Revenue | $553K+561.9% | $698K+266.3% | $1.0M+63993.1% | $271K+108.1% | $83K-50.5% | $191K+20.7% | $2K-98.9% | $130K+16.0% |
| Gross Profit | $619K+628.8% | $463K+71.4% | $1.0M+359.6% | $178K+41.1% | $85K-61.7% | $270K-0.4% | $219K+511.0% | $126K-80.7% |
| SG&A Expenses | $330K+111.9% | $297K+61.0% | $620K+128.1% | $201K-7.8% | $156K-18.3% | $185K-4.2% | $272K+195.6% | $218K-56.8% |
| Operating Income | $161K+183.1% | $36K+183.5% | $273K+245.5% | -$167K+25.1% | -$193K-105.0% | -$43K+6.8% | -$188K-181.0% | -$222K-149244.3% |
| EBITDA | $161K+183.7% | $37K+185.6% | $274K+246.3% | -$166K+24.8% | -$193K-107.1% | -$43K+5.4% | -$187K-180.3% | -$221K-14677.5% |
| Interest Expense | $215K+5.6% | $212K+4.7% | $211K-8.3% | $206K+8.4% | $203K+9.5% | $202K+9.4% | $229K+11.2% | $190K-1.1% |
| Income Tax | N/A | N/A | N/A | -$25K | N/A | $9K | N/A | N/A |
| Net Income | -$108K+80.8% | $2.2M+1528.7% | $436K+153.7% | -$420K+53.3% | -$563K-42.1% | -$155K+70.0% | -$813K | -$900K-337.4% |
| EPS (Basic) | -$0.02+83.3% | $0.45+1600.0% | $0.09+152.9% | -$0.09+50.0% | -$0.12-50.0% | -$0.03+70.0% | -$0.17-104.0% | -$0.18-350.0% |
| EPS (Diluted) | -$0.02+83.3% | $0.45+1600.0% | $0.09+152.9% | -$0.09+50.0% | -$0.12-50.0% | -$0.03+70.0% | -$0.17-104.0% | -$0.18-350.0% |
| Diluted Shares (Avg) | 5M0.0% | 5M0.0% | N/A | 5M0.0% | 5M0.0% | 5M0.0% | N/A | 5M0.0% |
Not reported in any period shown, so not listed: R&D Expenses.
CIRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.6M+58.6% | $2.5M+44.4% | $2.5M+64.1% | $1.9M-13.4% | $1.6M-28.1% | $1.7M-7.2% | $1.5M-17.1% | $2.2M+5.0% |
| Current Assets | $2.4M+69.4% | $2.3M+52.1% | $2.3M+77.0% | $1.7M-12.4% | $1.4M-29.4% | $1.5M-4.6% | $1.3M-16.5% | $1.9M+6.1% |
| Cash & Equivalents | $158K+3547.9% | $11K+836.9% | $10K | $19K | $4K | $1K-59.6% | N/A | N/A |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | N/A | N/A |
| Inventory | $1.0M+23.4% | $1.2M+39.9% | $1.1M+54.2% | $714K+3.2% | $836K+4.3% | $842K-1.9% | $737K-9.6% | $692K-20.9% |
| Accounts Receivable | $480K+2773.6% | $297K+132.5% | $366K+1326.1% | $55K-59.1% | $17K-85.1% | $128K+322.8% | $26K+19.1% | $135K-14.3% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | N/A | N/A |
| Total Liabilities | $25.6M-4.4% | $25.4M-3.4% | $27.6M+6.5% | $27.5M+6.4% | $26.8M+7.2% | $26.3M+8.8% | $25.9M+9.8% | $25.8M-42.8% |
| Current Liabilities | $22.6M-5.4% | $22.5M-4.3% | $24.7M+6.8% | $24.6M+6.9% | $23.9M+7.8% | $23.5M+9.7% | $23.1M+10.8% | $23.0M-45.8% |
| Non-Current Liabilities | $3.0M+3.9% | $3.0M+3.8% | $2.9M+3.8% | $2.9M+2.7% | $2.9M+2.0% | $2.8M+2.0% | $2.8M+1.9% | $2.8M+3.5% |
| Total Equity | -$23.0M+8.5% | -$22.9M+6.8% | -$25.1M-2.9% | -$25.5M-8.3% | -$25.1M-10.7% | -$24.6M-10.2% | -$24.4M-12.1% | -$23.6M+45.1% |
| Retained Earnings | -$60.2M+3.4% | -$60.1M+2.7% | -$62.3M-1.1% | -$62.8M-3.2% | -$62.4M-4.1% | -$61.8M-3.8% | -$61.6M-4.5% | -$60.8M+24.2% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
CIRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $184K+215.7% | -$59K+87.4% | -$306K-708.0% | -$405K-1911.8% | -$159K-4562.6% | -$468K-3204.2% | -$38K+64.1% | -$20K-137.4% |
| Depreciation & Amortization | $666+37.0% | $476-5.0% | $487-26.5% | $326-73.5% | $486-60.1% | $501-59.2% | $663-46.8% | $1K-10.0% |
| Financing Cash Flow | -$37K-122.8% | $61K-87.0% | $297K+1217.5% | $420K+1986.1% | $162K+39480.7% | $470K+3983.4% | $23K-72.6% | $20K+130.4% |
Not reported in any period shown, so not listed: Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
CIRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.8%+2.4pp | 39.9%-18.8pp | 49.2%-50.1pp | 39.6%-9.5pp | 50.4%-6.4pp | 58.7%-4.6pp | 99.3%+79.1pp | 49.2%-36.2pp |
| Operating Margin | 13.7% | 3.1%+12.5pp | 13.3%+98.4pp | -37.1%+49.6pp | -114.7% | -9.4%+1.4pp | -85.0% | -86.8%-86.8pp |
| Net Margin | -9.2% | 191.2% | 21.3% | -93.6% | -334.1% | -33.7% | -368.0% | -351.4% |
| Return on Assets | -4.2%+30.1pp | 88.2%+97.1pp | 17.4%+70.4pp | -21.9%+18.7pp | -34.3%-16.9pp | -8.9%+18.6pp | -53.0% | -40.6%-30.9pp |
| Current Ratio | 0.100.0x | 0.100.0x | 0.090.0x | 0.070.0x | 0.060.0x | 0.060.0x | 0.060.0x | 0.080.0x |
| Asset Turnover | 0.45+0.3x | 0.46+0.2x | 0.82+0.7x | 0.23+0.1x | 0.10-0.1x | 0.260.0x | 0.140.0x | 0.12-0.2x |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$25.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.09), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where Cirtran Ranks
Frequently Asked Questions
What is Cirtran's annual revenue?
Cirtran (CIRX) reported $3.1M in total revenue for fiscal year 2025. This represents a 141.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cirtran's revenue growing?
Cirtran (CIRX) revenue grew by 141.1% year-over-year, from $1.3M to $3.1M in fiscal year 2025.
Is Cirtran profitable?
No, Cirtran (CIRX) reported a net income of -$702K in fiscal year 2025, with a net profit margin of -22.4%.
What is Cirtran's EBITDA?
Cirtran (CIRX) had EBITDA of -$128K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cirtran's gross margin?
Cirtran (CIRX) had a gross margin of 49.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cirtran's operating margin?
Cirtran (CIRX) had an operating margin of -4.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cirtran's net profit margin?
Cirtran (CIRX) had a net profit margin of -22.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cirtran's operating cash flow?
Cirtran (CIRX) recorded an outflow of $1.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cirtran's total assets?
Cirtran (CIRX) had $2.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Cirtran's current ratio?
Cirtran (CIRX) had a current ratio of 0.09 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Cirtran's return on assets (ROA)?
Cirtran (CIRX) had a return on assets of -27.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cirtran's P/E ratio?
Cirtran (CIRX) trades at 0.1x earnings, its market capitalization divided by net income of $2.1M net income, trailing 12 months to June 30, 2026. The market capitalization is $188K as of Sep 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Cirtran's price-to-sales ratio?
Cirtran (CIRX) trades at 0.0x sales, its market capitalization divided by revenue of $4.8M revenue, trailing 12 months to June 30, 2026. The market capitalization is $188K as of Sep 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Cirtran's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Cirtran (CIRX) held $10K in cash, cash equivalents and investments, and reported an operating cash outflow of $1.3M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Cirtran's debt-to-equity ratio negative or not reported?
Cirtran (CIRX) has negative shareholder equity of -$25.1M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Cirtran's Altman Z-Score?
Cirtran (CIRX) has an Altman Z-Score of -44.35, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cirtran's Piotroski F-Score?
Cirtran (CIRX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cirtran's earnings high quality?
Cirtran (CIRX) reported a net loss of $702K while operations used $1.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cirtran cover its interest payments?
Cirtran (CIRX) reported an operating loss of $130K against $823K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.